VolitionRx Limited (NYSE American: VNRX) is set to release its quarterly earnings with an expected EPS loss of $0.06 and revenue of approximately $545,340.
The company’s Nu.Q® Cancer diagnostics test, capable of detecting 21 types of human cancers, positions VolitionRx as a potential leader in the $20 billion liquid biopsy industry.
Despite its innovative advancements, VolitionRx faces financial challenges, including a negative P/E ratio of -1.60 and a current ratio of 0.22, indicating potential liquidity issues.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company known for its innovative cancer diagnostics. The company is set to release its quarterly earnings on March 24, 2025, with analysts predicting an EPS loss of $0.06 and revenue of approximately $545,340. The earnings report will be released before the market opens.
VolitionRx is making strides in the cancer diagnostics field with its Nu.Q® Cancer diagnostics test. This test can detect 21 types of human cancers with high specificity, as highlighted by PR Newswire. The test’s rapid and low-cost nature positions it as a potential game-changer in the $20 billion liquid biopsy industry.
The company has also introduced a new industry primer focusing on lung cancer, emphasizing the Nu.Q® Cancer Test’s potential to transform the $4 billion lung cancer market. The test aims to improve diagnosis, treatment, and monitoring, offering a low-cost, easy-to-administer solution that requires only a small blood sample.
VolitionRx is conducting a clinical study at National Taiwan University Hospital to validate its Nu.Q® Lung Cancer Test. This study, involving 500 patients, aims to differentiate between malignant and benign pulmonary nodules. The test has already shown promise in distinguishing nodules found through LDCT screening.
Despite its innovative advancements, VolitionRx faces financial challenges. The company has a negative P/E ratio of -1.60, indicating a lack of profitability. Its price-to-sales ratio of 40.62 and enterprise value to sales ratio of 40.99 suggest a high valuation relative to sales. Additionally, the current ratio of 0.22 may indicate potential liquidity issues.
